Share Name Share Symbol Market Type Share ISIN Share Description
Yourgene Health Plc LSE:YGEN London Ordinary Share GB00BN31ZD89 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.25 -1.64% 15.00 1,773,750 16:35:26
Bid Price Offer Price High Price Low Price Open Price
16.00 16.50 16.25 15.25 15.25
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 16.61 -3.38 -0.40 108
Last Trade Time Trade Type Trade Size Trade Price Currency
16:35:26 UT 50,462 15.00 GBX

Yourgene Health (YGEN) Latest News

More Yourgene Health News
Yourgene Health Investors    Yourgene Health Takeover Rumours

Yourgene Health (YGEN) Discussions and Chat

Yourgene Health Forums and Chat

Date Time Title Posts
20/5/202007:42YourGene to Infinity2,121
04/5/202008:06Partnership with Novacyt 2
30/3/202008:20Yourgene Health at the UK Investor Show3

Add a New Thread

Yourgene Health (YGEN) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Yourgene Health trades in real-time

Yourgene Health (YGEN) Top Chat Posts

Yourgene Health Daily Update: Yourgene Health Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker YGEN. The last closing price for Yourgene Health was 15.25p.
Yourgene Health Plc has a 4 week average price of 14.25p and a 12 week average price of 11.63p.
The 1 year high share price is 22p while the 1 year low share price is currently 11.63p.
There are currently 723,145,182 shares in issue and the average daily traded volume is 2,612,071 shares. The market capitalisation of Yourgene Health Plc is £108,471,777.30.
phatomtraider: As before play the ball, not the player. For LTHs you chaps surprisingly post absolutely nothing in terms of scientific interest, no reference to facts, figures, lab capacity or contractual assessments. Instead you personalise any assessment of the poor performance of the share price and the Company. For what reason, given that the Directors had already misled investors here on a few occasions last year? 1 poster cannot affect a stock of 721m+ shares. Especially when contrasted to BB rampers and the Twitter pump and dump brigade. So get over yourselves and frankly grow up. Or better yet, rather than sending lazy 1-line ramping posts degrading posters at a personal level when they reference RNS in their posts, perhaps you know post something positive about the Company? I would look more at the trades that happened yesterday to understand why you are flatlining, rather than attribute my posting prowess. You were warned from circa 20th March onwards when the share price was closer to 17p that there would be a slide here towards the Results. The share price performance has already proved one of us right. Just let the Seller out, or ramp to give them a better price. Your choice.
phatomtraider: Christ it is pathetic to even think that a poster on a BB, averaging a solitary post a day, can influence the share price of a share with 721m shares. The share price will do what the share price will do regardless of my solitary posts, or my holdings. Cannot see the calls for balanced and informed posts stopping those ramping on this BB, Twitter or LSE. So please. You were informed when the share price was higher that a repeat of what happened last year with the sale of the Euciligene Directors shares and Options was going to happen again. If it hasn't then how can you explain the lacklustre share price if someone is not selling in the background, and into any rise? Rather than ramping to give these Directors a better price, just buy after the Results. I mean duh!?
phatomtraider: Options exercised will add 2,553,333 new ordinary shares on or around 26 March 2021. Exercise price sub-10p so I would expect them to be sold pre-Results as not expecting a spike especially after given GDR results today. Massively inflated share price to non-existent sales in PCR space. Mugs following the dodgy chartists and paid-for rampers will just be propping up the share price so that the Directors can dump their shares pre-Results from tomorrow onwards.
redartbmud: Agreed. Should they choose to place additional shares, the massive recent underperformance will weigh heavily on the strike price that can be achieved. That especially should they want existing shareholders to take up a significant percentage on the new shares. They will be raw from the losses that they have already sustained. I am unimpressed with the way that the Rns is set out. At best it is muddled. To my 'deferred' deferred means non-commitment. i.e. No guarantee that Ygen will be awarded the contracts, should they indeed e placed at levels and prices that may have existed. pre-covid. There is an easy get out for management, who can just claim that customers reset their budgets and activity levels to meet revised demand. I can only see the share price drifting down further in the short term. Not sure that anyone would be interested in a takeover, except at very distressed price.
apad: I bought YGEN as a recovery play before the pandemic after they stopped litigation as a recovery play. The pandemic has put this on hold and the corvid activity is a patch to keep the company going. YGEN's revenue per employee is £126k and 5 years of revenue will buy the company. These are not good figures and there are other poor metrics that demonstrate its current dilemma. I wouldn't buy shares now, but have decided to hold as a survivability play. Nevertheless the share price, even after the recent fall, is not attractive - given the risks and the company metrics. I am expecting share price weakness to continue until (unless) they can report revenue growth well above the last FY at 5%. Good luck to all of us stuck in this potential energy well - both the optimistic and the pessimistic 😊 apad
twix386: Ngen, could you advise the year that all the regular and varied positivity simply translates into a worthy share price?Seems to me one year morphs into the next with renewed hopes and yet substandard share price appreciation ad-infinitum.YourGene: to date a story of a new hiccup following a new hope, resulting in underwhelming shareholder value.Get a 25p T/O. 20p++ should certainly be achievable and be done with one let down after another!
superg1: Why they get recorded as sells? The software doesn't recognise buy or sells, all it knows is the mid price, above it and it records a buy, below it and it records a sell. The share price has been on a slide, after hours big numbers tends to mean late reported selling (based on the share price trend), numbers that get reported when they are completed (stock sold) as per late report rules which allow late reports when they are above 'normal market size'. Just saying, I noted the late report big numbers on this one so had a look.
ngen yap: There is no positive spin to be made on the performance of the share price! It's underperformed, period. Doesn't mean the company isn't progressing well and that's what I remain confident in. And hopefully share price will take care of itself or we get acquired!RE share options, I'll be disappointed if they are issued at nominal value but these are at market value each time. So company actually gets the cash IF options exercised. A good motivational tool to get share price up for it to be worth anything. E.g. the 18p options are worth nothing at the moment.Anyway, don't fret, it's the weekend. Next week is another trading week.
pedr01: "YGEN share price underperforming relative to overall markets, especially since the impediment impacting H1 removed and lots of growth avenues." Not sure that is true. Just a bit of frustration combined with a bit of hindsight investing seeing other (select) companies moving forwards. FTSE100 6541/7604 => -14% FTSE250 20171/22108 => -8.8% FTSE AIM 1069/963 => +11.0% YGEN 16.5/13.88 => +18.9% relative to 02 Jan 2020 Personally, I just re-visit my buy notes and decide whether I think the company has moved forwards or backwards against why I bought in the first place. In my view everything is moving forwards, and if they meet expectations (or even close) and achieve maiden earnings (not just ebitda) then that should start the share price moving forwards. Unfortunately ... having asked the question of whether the forecasts take account of earn-outs the reply was slightly "muddied", and to avoid disappointment I think it is best to assume that forecasts DO NOT account for earn-outs due in the period.
ngen yap: YGEN share price underperforming relative to overall markets, especially since the impediment impacting H1 removed and lots of growth avenues. When I am frustrated with it, I ask myself. Do I like the space YGEN is in? Yes. Do I like it's products and services? Yes. Do I think management can deliver? Yes. Is the company well funded? Yes. Does it have USP/ IP? Yes. Then I always end up adding......hehe.....this will come good. Looking fwd to interim update, numbers won't be great but am hopeful on outlook.
Yourgene Health share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Yourgene H..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210419 04:16:05